Prolactinoma

Endocrinology · Ward Pathways · Free — no sign-in

Galactorrhea, amenorrhea, ↓libido, bitemporal hemianopia

  1. Confirm: Prolactin level → pituitary MRI
  2. Treat: Cabergoline / bromocriptine (dopamine agonist) — first-line even for macroadenoma
  3. Refractory / visual loss → transsphenoidal surgery

Order set

  • Prolactin
  • Pituitary MRI
  • TFT, pregnancy test
  • Visual fields (macro)

Criteria

AdmitApoplexy or visual compromise
DischargeDopamine agonist started, endocrine + fields follow-up
Clinical detail — differentials, red flags, pitfalls, disposition
Red flags
  • Visual field defect
  • Apoplexy
Differentials
  • Drug-induced hyperprolactinaemia
  • Pregnancy
  • Hypothyroidism
  • Stalk effect
Common mistakes
  • MRI before excluding drugs/pregnancy
  • Surgery first-line
Disposition & follow-up

Dopamine agonist first-line; surgery if refractory.

Discharge package
MedicationsDopamine agonist
Follow-upEndocrine; prolactin + fields + MRI
Warning symptomsVisual change, severe headache
💊 Treatment detail — doses & preparation
Cabergolinedopamine agonist
Dose0.25–0.5 mg twice weekly, titrate monthly (prolactinoma/acromegaly adjunct)
Preparation0.5 mg tablets with food
MonitorProlactin monthly, impulse-control disorders, cardiac valve (high cumulative dose)
Bromocriptinedopamine agonist
Dose2.5–15 mg/day divided (alternative; preferred if pregnancy planned)
Preparation2.5 mg tablets with food
MonitorNausea, orthostasis, impulse control
📖 Endocrine Society HyperprolactinaemiaReviewed July 2026

← Hyperaldosteronism (Conn)  ·  Stroke (Ischemic) →

More Endocrinology pathways

Part of Endocrinology in Ward Pathways — open the interactive version.

ICU Decoded — original critical-care and internal-medicine pathways by Dr Javed Akhtar, each cited to a current guideline. For education and quick reference; verify every dose against local protocols before prescribing.

Open the app · Ward Pathways — 113 free cases · ICU Decoded chapters · Aladin Chirag bedside tools

About · Medical disclaimer · Privacy · Contact